Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.

Authors

Gawahir A Ali, Maha Y Al-Jabri, Wael Goravey, Khaled M Shunnar, Mostafa Najim, Joanne Daghfal, Jemal M Hamid, Ahmed M Hassan, Emad B Ibrahim, Faiha Eltayeb, Ali A Sultan, Hamad Abdel Hadi, Muna Al Maslamani, Marc Stegger, Ali S Omrani

Published in

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

The aim of this study was to explore the clinical, microbiological, and molecular characteristics of Stenotrophomonas maltophilia bacteraemia, outcomes, and risk factors associated with mortality.
This was a nationwide retrospective cohort study of patients with S. maltophilia bacteraemia during the period between January 2017 and December 2021. MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for susceptibility testing, and Illumina for whole genome sequencing. Kaplan-Meier survival analysis and a multivariable Cox regression model were utilized to assess independent predictors of 90-day all-cause mortality.
Ninety patients were included, with a median age of 51.5 years (IQR 37-61), and 25.6% were females. The most common underlying medical conditions included diabetes mellitus (42.2%), and haematological malignancy (23.3%); and 64.4% were immunosuppressed. The most common sources of bacteraemia were the respiratory tract (38.9%) and vascular lines (25.6%). In vitro susceptibility rates were highest for trimethoprim-sulfamethoxazole (98.9%), and levofloxacin (61.1%). Sequencing demonstrated extensive genomic heterogeneity, and sul1 gene was detected in only one strain. The most frequent therapy was trimethoprim-sulfamethoxazole, monotherapy (77.8%) or in combinations (6.7%), for a median duration of 10 days (IQR 5-14). All-cause 90-day mortality was 44.4%. Receiving trimethoprim-sulfamethoxazole was associated with improved 90-day survival (log-rank P < 0.001), and was independently associated with lower mortality in the multivariable Cox model (hazard ratio 0.21, 95% confidence interval 0.06 to 0.74).
S. maltophilia blood isolates are genomically diverse and remain mostly susceptible to trimethoprim-sulfamethoxazole. Using trimethoprim-sulfamethoxazole for patients with S. maltophilia bacteraemia appears to be associated with improved survival.

PMID:
42611349
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.